Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari

Invokana Clinical Trials

Checklist Icon

Prescribing Information

Great Britain Northern Ireland

Key Studies

Click on a clinical study below:

Ket Study
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

Perkovic V, Jardine MJ, Neal B, et al.

The New England Journal of Medicine 2019;380(24):2295-2306

Ket Study
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Perkovic V, de Zeeuw D, Mahaffey KW, et al.
The Lancet Diabetes & Endocrinology 2018;6(9):691-704

Ket Study
Kidney disease and increased mortality risk in type 2 diabetes.

Afkarian M, Sacha M, Kestenbaum B, et al.
Journal of the American Society of Nephrology 2013;24(2):302-308

Invokana vs other SGLT2 inhibitors

Click on a clinical study below:

Consistent reductions in HbA1c with Invokana 100 mg and 300 mg

Click on a clinical study below:

Ket Study
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Forst T, Guthrie R, Goldenberg R, et al.
Diabetes, Obesity & Metabolism 2014;16(5):467-477

Ket Study
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.

Wilding JP, Charpentier G, Hollander P, et al.
International Journal of Clinical Practice 2013;67(12):1267-1282

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.